About This Fund
Sofinnova Capital XI is the eleventh iteration of Sofinnova Partners’ flagship venture capital strategy, closing with €650 million in commitments. This oversubscribed fund reflects strong demand from a diversified global investor base, including sovereign wealth funds, corporates, insurers, foundations, and family offices. A majority of existing limited partners returned, alongside new institutional investors, underscoring confidence in the firm’s long-standing life sciences expertise. Focused on early-stage investing, Sofinnova Capital XI targets seed and Series A rounds in the biotechnology and medical device sectors. The fund is designed to take meaningful initial stakes and support portfolio companies through multiple financing rounds. This capital will fuel high-potential ventures working to transform scientific discoveries into patient-ready solutions, particularly in areas with significant unmet medical needs. The fund will invest across Europe and North America, leveraging Sofinnova’s presence in Paris, London, and Milan, as well as its networks in the United States. The cross-border investment team will source and nurture opportunities at the intersection of innovation and clinical translation. The firm’s hands-on approach includes company building, board-level involvement, and strategic guidance from preclinical development to commercialization.